UK's C4X Discovery signs $400 mln licensing deal with AstraZeneca

C4X Discovery Holdings

28/11/2022 07:23

LONDON, Nov 28 (Reuters) - British drug discovery
company C4X Discovery  C4XD.L  said AstraZeneca  AZN.L  had
signed a licence worth up $402 million to develop an oral
therapy for the treatment of inflammatory and respiratory
diseases using its NRF2 Activator programme.
    C4XD said on Monday it would receive pre-clinical milestone
payments worth up to $16 million ahead of the first clinical
trial, including $2 million upfront.  
    In addition, C4XD said it would receive a further
potential $385.8 million in clinical development and commercial
milestones and tiered mid-single digit royalties upon
commercialisation of any treatment.
 
 (Reporting by Paul Sandle; editing by Sarah Young)
 ((paul.sandle@thomsonreuters.com; +44 20 7542 6843; Reuters
Messaging: paul.sandle.thomsonreuters.com@reuters.net))